26-Sep-2024
No headlines found.
Globe Newswire (Thu, 19-Sep 5:24 PM ET)
Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield
Globe Newswire (Thu, 12-Sep 4:31 PM ET)
Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results
Globe Newswire (Tue, 13-Aug 4:05 PM ET)
Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024
Globe Newswire (Tue, 30-Jul 5:05 PM ET)
Singular Genomics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Globe Newswire (Mon, 15-Jul 4:05 PM ET)
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
Singular Genomics Systems trades on the NASDAQ stock market under the symbol OMIC.
As of September 26, 2024, OMIC stock price declined to $15.51 with 47,269 million shares trading.
OMIC has a beta of 3.52, meaning it tends to be more sensitive to market movements. OMIC has a correlation of 0.22 to the broad based SPY ETF.
OMIC has a market cap of $38.71 million. This is considered a Sub-Micro Cap stock.
Last quarter Singular Genomics Systems reported $737,000 in Revenue and -$8.57 earnings per share. This beat revenue expectation by $337,000 and exceeded earnings estimates by $.31.
In the last 3 years, OMIC traded as high as $533.11 and as low as $5.34.
The top ETF exchange traded funds that OMIC belongs to (by Net Assets): VTI, VXF.
OMIC has underperformed the market in the last year with a return of +28.7%, while SPY returned +34.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in OMIC shares. However, OMIC has outperformed the market in the last 3 month and 2 week periods, returning +78.3% and +173.8%, while SPY returned +5.4% and +3.5%, respectively. This indicates OMIC has been having a stronger performance recently.
OMIC support price is $14.10 and resistance is $17.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMIC shares will trade within this expected range on the day.